The Role of Eosinophils in Immunotherapy

Overview

Journal Curr Allergy Asthma Rep

Specialties Allergy & Immunology
Pulmonary Medicine

Date 2020 Jan 9

PMID 31912246

Citations 4

Authors

Joseph Cafone

Melanie A Ruffner

Jonathan M Spergel

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The purpose of this review is to provide a brief discussion on the differential diagnosis for peripheral eosinophilia. We will then focus on targeted immunotherapies for atopic disease, their effects on absolute peripheral eosinophil counts, and use of peripheral eosinophils as a predictor of treatment response.

Recent Findings: In atopic disease, lower absolute peripheral eosinophil counts are typically associated with improved outcomes. Much of the current evidence on eosinophils as a biomarker comes from post hoc analyses in therapeutic immunotherapy. While changes in eosinophilia were not the primary outcome of interest in many studies, some patterns did emerge. Cytolytic monoclonal antibodies AK002 and benralizumab completely reduce peripheral and tissue eosinophil numbers. Dupilumab may have paradoxical transient eosinophilia despite observed clinical efficacy. Atopic inflammation is complex largely due to the various cytokines which affect eosinophil activation, proliferation, differentiation, and survival. This demonstrates the challenges of using peripheral eosinophilia alone as a biomarker for atopic disease activity. More attention should spotlight how different immunotherapy modalities affect eosinophil-driven responses.

Citing Articles

A Critical Review of the Hydrometallurgy and Pyrometallurgical Recovery Processes of Platinum Group Metals from End-of-Life Fuel Cells.

Mvokwe S, Oyedeji O, Agoro M, Meyer E, Rono N Membranes (Basel). 2025; 15(1).

PMID: 39852254 PMC: 11766938. DOI: 10.3390/membranes15010013.

Eosinophilia in a patient with ankylosing spondylitis treated with prolonged adalimumab only.

He J, Luo J, Yang Q, Yuan F Arch Med Sci. 2022; 18(2):564-567.

PMID: 35316919 PMC: 8924826. DOI: 10.5114/aoms/146793.

Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity.

Dagher R, Kumar V, Copenhaver A, Gallagher S, Ghaedi M, Boyd J Eur Respir J. 2021; 59(3).

PMID: 34289975 PMC: 8923056. DOI: 10.1183/13993003.04306-2020.

Advances and novel developments in molecular allergology.

Uzulmez O, Kalic T, Breiteneder H Allergy. 2020; 75(12):3027-3038.

PMID: 32882057 PMC: 7756543. DOI: 10.1111/all.14579.

The role of eosinophils in immunotherapy: Retraction.

Curr Opin Allergy Clin Immunol. 2020; 20(3):329.

PMID: 32332214 PMC: 7448293. DOI: 10.1097/01.all.0000666240.38347.de.

References

Khatri S, Moore W, Gibson P, Leigh R, Bourdin A, Maspero J . Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2018; 143(5):1742-1751.e7. DOI: 10.1016/j.jaci.2018.09.033. View

Rothenberg M, Klion A, Roufosse F, Kahn J, Weller P, Simon H . Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008; 358(12):1215-28. DOI: 10.1056/NEJMoa070812. View

Spergel J, Rothenberg M, Collins M, Furuta G, Markowitz J, Fuchs 3rd G . Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2011; 129(2):456-63, 463.e1-3. DOI: 10.1016/j.jaci.2011.11.044. View

Spergel J, Dellon E, Liacouras C, Hirano I, Molina-Infante J, Bredenoord A . Summary of the updated international consensus diagnostic criteria for eosinophilic esophagitis: AGREE conference. Ann Allergy Asthma Immunol. 2018; 121(3):281-284. PMC: 6139263. DOI: 10.1016/j.anai.2018.05.035. View

Jin J, Butterfield J, Weiler C . Hematologic Malignancies Identified in Patients with Hypereosinophilia and Hypereosinophilic Syndromes. J Allergy Clin Immunol Pract. 2015; 3(6):920-5. DOI: 10.1016/j.jaip.2015.06.009. View

Woodruff P, Khashayar R, Lazarus S, Janson S, Avila P, Boushey H . Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol. 2001; 108(5):753-8. DOI: 10.1067/mai.2001.119411. View

Burbank A, Burks W . Food specific oral immunotherapy: a potential treatment for food allergy. Expert Rev Gastroenterol Hepatol. 2015; 9(9):1147-59. DOI: 10.1586/17474124.2015.1065177. View

Simpson E, Bieber T, Guttman-Yassky E, Beck L, Blauvelt A, Cork M . Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016; 375(24):2335-2348. DOI: 10.1056/NEJMoa1610020. View

Brightling C, Chanez P, Leigh R, OByrne P, Korn S, She D . Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015; 3(9):692-701. DOI: 10.1016/S2213-2600(15)00197-6. View

10.

Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M . Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. Chest. 2016; 150(4):789-798. DOI: 10.1016/j.chest.2016.03.032. View

11.

Wasserman R, Hague A, Pence D, Sugerman R, Silvers S, Rolen J . Real-World Experience with Peanut Oral Immunotherapy: Lessons Learned From 270 Patients. J Allergy Clin Immunol Pract. 2018; 7(2):418-426.e4. DOI: 10.1016/j.jaip.2018.05.023. View

12.

Egan M, Furuta G . Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2018; 121(2):162-167. DOI: 10.1016/j.anai.2018.06.013. View

13.

Lue K, Lin Y, Sun H, Lu K, Hsieh J, Chou M . Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol. 2006; 17(6):408-15. DOI: 10.1111/j.1399-3038.2006.00443.x. View

14.

Castro M, Wenzel S, Bleecker E, Pizzichini E, Kuna P, Busse W . Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014; 2(11):879-890. DOI: 10.1016/S2213-2600(14)70201-2. View

15.

Gauvreau G, OByrne P, Boulet L, Wang Y, Cockcroft D, Bigler J . Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014; 370(22):2102-10. DOI: 10.1056/NEJMoa1402895. View

16.

Sanderson C . Eosinophil differentiation factor (interleukin-5). Immunol Ser. 1990; 49:231-56. View

17.

Wilson D, Irani A, Walker S, Jacobson M, Mackay I, Schwartz L . Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy. 2001; 31(11):1705-13. DOI: 10.1046/j.1365-2222.2001.01231.x. View

18.

Pelaia C, Calabrese C, Vatrella A, Busceti M, Garofalo E, Lombardo N . Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. Biomed Res Int. 2018; 2018:4839230. PMC: 5971345. DOI: 10.1155/2018/4839230. View

19.

Kolbeck R, Kozhich A, Koike M, Peng L, Andersson C, Damschroder M . MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010; 125(6):1344-1353.e2. DOI: 10.1016/j.jaci.2010.04.004. View

20.

Bachert C, Sousa A, Lund V, Scadding G, Gevaert P, Nasser S . Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. J Allergy Clin Immunol. 2017; 140(4):1024-1031.e14. DOI: 10.1016/j.jaci.2017.05.044. View